Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00113204
Recruitment Status : Completed
First Posted : June 7, 2005
Last Update Posted : May 20, 2008
Information provided by:
Infinity Pharmaceuticals, Inc.